Induction of Atrial Fibrillation by Neutrophils Critically Depends on CD11b/CD18 Integrins

Kai Friedrichs¹,²,³, Matti Adam³, Lisa Remane¹,², Martin Mollenhauer¹,², Volker Rudolph¹,², Tanja K. Rudolph¹,², René P. Andrié⁴, Florian Stöckigt⁴, Jan W. Schrickel⁴, Thorben Ravekes¹,², Florian Deuschl³, Georg Nickenig⁴, Stephan Willems⁵, Stephan Baldus¹,², Anna Klinke¹,²,

¹ Heart Center, University of Cologne, Cologne, Germany, ² Cologne Cardiovascular Research Center, University of Cologne, Cologne, Germany, ³ Department of General and Interventional Cardiology, University Heart Center Hamburg, Hamburg, Germany, ⁴ Department of Medicine-Cardiology, University Hospital of Bonn, Bonn, Germany, ⁵ Department of Electrophysiology, University Heart Center Hamburg, Hamburg, Germany

Abstract

**Background:** Recent observational clinical and ex-vivo studies suggest that inflammation and in particular leukocyte activation predisposes to atrial fibrillation (AF). However, whether local binding and extravasation of leukocytes into atrial myocardium is an essential prerequisite for the initiation and propagation of AF remains elusive. Here we investigated the role of atrial CD11b/CD18 mediated infiltration of polymorphonuclear neutrophils (PMN) for the susceptibility to AF.

**Methods and Results:** C57Bl/6J wildtype (WT) and CD11b/CD18 knock-out (CD11b⁻/⁻) mice were treated for 14 days with subcutaneous infusion of angiotensin II (Ang II), a known stimulus for PMN activation. Atria of Ang II-treated WT mice were characterized by increased PMN infiltration assessed in immunohistochemically stained sections. In contrast, atrial sections of CD11b⁻/⁻ mice lacked a significant increase in PMN infiltration upon Ang II infusion. PMN infiltration was accompanied by profoundly enhanced atrial fibrosis in Ang II treated WT as compared to CD11b⁻/⁻ mice. Upon in-vivo electrophysiological investigation, Ang II treatment significantly elevated the susceptibility for AF in WT mice if compared to vehicle treated animals given an increased number and increased duration of AF episodes. In contrast, animals deficient of CD11b/CD18 were entirely protected from AF induction. Likewise, epicardial activation mapping revealed decreased electrical conduction velocity in atria of Ang II treated WT mice, which was preserved in CD11b⁻/⁻ mice. In addition, atrial PMN infiltration was enhanced in atrial appendage sections of patients with persistent AF as compared to patients without AF.

**Conclusions:** The current data critically link CD11b-integrin mediated atrial PMN infiltration to the formation of fibrosis, which promotes the initiation and propagation of AF. These findings not only reveal a mechanistic role of leukocytes in AF but also point towards a potential novel avenue of treatment in AF.

Introduction

Atrial fibrillation (AF) stands out as the most prevalent human rhythm disorder. Atrial fibrillation is associated with an increased long-term risk of heart failure, remains a principal and common cause of stroke and doubles mortality [1–4]. Despite its prevalence and its contribution to morbidity and mortality, treatment strategies still remain scarce. Ion channel directed therapies as well as interventional strategies are most effective only in a subset of patients: whereas patients with non permanent, paroxysmal AF can be treated in the majority of cases, individuals with permanent AF in large part do not derive benefit from anti-arrhythmic and interventional therapy, respectively, calling for adjunct therapies [5,6].

Therefore, a better understanding of the underlying pathophysiology is of foremost importance. An accumulating body of evidence suggests that atrial fibrosis plays a major role in the pathogenesis of atrial fibrillation: Increased deposition of interstitial matrix such as collagen I and III and fibronectin impedes atrial conduction, allowing for an increased electrical ectopy and reentry. Moreover, matrix turnover - by exposing cytokines, adhesion molecules and growth factors – propagates a proinflammatory milieu [7–9]. In fact, inflammation appears to be a critical confounder for structural remodeling of the atria and thus for the genesis of atrial fibrillation [10,11]. Clinical studies support this view by revealing a predictive role of biomarkers such as C-reactive protein (CRP), interleukin (IL)-6 and tumor necrosis factor (TNF)-2 with respect to AF occurrence, persistence,
recurrence and left atrial dimensions. [12–22]. More so, clinical observations revealed leukocytes to be of critical significance for this disease in humans: Leukocytes were identified in atrial tissue of AF patients even without an underlying structural heart disease [11], and postoperative atrial leukocyte infiltration independently predicted postsurgery AF [23,24]. Of note, enzyme systems stored in leukocytes such as myeloperoxidase (MPO) and matrix metalloproteinase (MMP)-2, enzymes known to accelerate tissue remodeling, were also predictive of AF burden and recurrence of this disease following interventional ablation [25,26].

Activation and extravasation of leukocytes and in particular of polymorphonuclear neutrophils (PMN), the most abundant subset of leukocytes and the major constituents of the innate immune system, depend on the activation state of the local endothelium – which releases local cytokines and expresses adhesion molecules. As of at least similar importance, PMN adhesion critically relies on the expression of integrins on the leukocytes outer membrane: PMN express CD11b/CD18 integrins (Mac1), which allow binding to adhesion molecules like intercellular adhesion molecule-1 (ICAM-1) on the endothelial cell surface – the principal prerequisite for the leukocytes subsequent extravasation [27–29]. Notably, CD11b/CD18 integrins not only interact with cellular proteins, they also bind with high affinity to components of the extracellular matrix like fibrinogen/fibrin and collagen and to polysaccharides like heparan sulfates [30–32]. Furthermore, CD11b/CD18 takes central stage in PMN activation: Effector pathways downstream of CD11b/CD18 include NADPH-oxidase activation with concomitant formation of superoxide and release of granular proteins [33,34]. Interestingly, it has been shown lately, that PMN release MPO to endothelial cells via a direct CD11b/CD18-integrin mediated intercellular link [35].

We observed recently, that MPO promotes fibrosis and thereby increases AF susceptibility [25]. However, to date a direct mechanistic link between AF and PMN localization within the atrial tissue has not been established. Here we tested the impact of CD11b/CD18 integrins on AF susceptibility in a murine model of AF.

Methods

Ethics Statement

All animal studies were approved by the local authorities: Behörde für Soziales, Familie, Gesundheit und Verbraucherschutz, Fachabteilung Veterinärwesen und Lebensmittelsicherheit, Hamburg, G09/064 and Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen, 84-02.04.2012.A307) and the Universities of Hamburg and Cologne Animal Care and Use Committees. All surgical interventions were performed under isoflurane anesthesia and buprenorphine analgesia to minimize suffering of animals.

Patient studies were approved by the local Ethics Committee (Hamburg) and were performed in accordance with the Declaration of Helsinki and with written informed consent.

Animals and experimental design

Male C57Bl/6J WT and CD11b/CD18-deficient (Itgam tm1-Myd/J, CD11b ^+/−^) mice (8–10 weeks of age, Jackson Laboratory) were treated with either angiotensin II (Ang II, 1.3 ng/g/min) or vehicle via subcutaneously implanted osmotic minipumps (Alzet, model 1002) for 2 weeks. We did not observe any differences in mortality, wound infection or wound healing after minipump implantation in CD11b ^+/−^ compared to WT mice. These findings were consistent with previous work that reported similar observations [36].

Electrophysiological investigation

Mice were anaesthetized with isoflurane and placed in supine position on a heating pad. An octopolar electrophysiological catheter (1.1 F, Scisense) was inserted via the right jugular vein to the right atrium and ventricle. Surface ECG was analyzed under stable baseline conditions for at least 3 min. Heart rate, P wave duration, QRS duration and QTc interval were measured by successive evaluation of 10 RR complexes in the most distinguishable tracings. Electrophysiological investigation with induction of arrhythmias was performed as described previously [37]. Intracardiac atrial and ventricular recording and atrial stimulation maneuvers were performed using a CardioTek EPTracer (Biotronik). Bipolar electrograms were obtained from each electrode pair during the whole procedure. Programmed atrial stimulation was performed at pacing stimulus amplitudes of 1.0 and 2.0 mA with 7 stimuli fixed rate at S1S1 cycle length of 120 ms, 110 ms and 100 ms, respectively, with one short coupled extra stimulus with a 10 ms-stepwise S1S2 reduction starting at cycle length of 80 ms down to 10 ms. Atrial refractory period (ARP) was determined, which was defined as longest S1S2 with absent atrial response in the most representative intracardiac tracing. Atrial burst stimulation was performed for 1 sec (three times consecutively) at S1 stimulation cycle lengths starting at 50 ms with 10-ms stepwise reduction down to 10 ms at pacing stimulus amplitudes of 1.0 and 2.0 mA. Between these stimulation procedures, a 10-sec recovery period was maintained. Atrial fibrillation was defined by presence of rapid and fragmented atrial electrograms in combination with irregular AV-nodal conduction and ventricular rhythm with a duration of these atrial electrograms of more than one second [38]. Number of AF episodes and AF duration (last stimulus-spike to the first sinus-rhythm P wave) were analyzed.

Thereafter, blood was drawn from the caval vein into heparinized syringes, hearts were flushed with saline via left ventricular puncture and hearts were excised. Hearts were either fixed in 3.7% paraformaldehyde solution and embedded in paraffin, embedded in optimal cutting temperature compound (OCT) and frozen to −80°C or atria and ventricles were dissected and snap frozen in liquid nitrogen.

Langendorff-perfused hearts and epicardial mapping

For investigation of myocardial conduction velocities and homogeneity of conduction, hearts were Langendorff-perfused and epicardial activation mapping (EAM) using a 36-electrode array (FlexMEA36, Multi Channel Systems, interelectrode distance: 300 μm) was performed [37]. For this, hearts were excorporated and dissected from surrounding tissue in ice-cold Krebs-Henseleit buffer. Following cannulation of the aorta, the heart was immersed in a water-jacketed chamber and further fixed on a moistened support. Hearts were then retrogradely perfused in a Langendorff-apparatus (Radnoti Technologies Inc.) at constant pressure perfusion (80 mmHg, resulting in coronary flow between 2–2.5 ml/min). The perfusate composition was (in mM): NaCl 110, KCl 4.6, MgSO4 1.2, CaCl2, Na2HPO4 2, NaHCO3 25, glucose 8.3, Na-pyruvate 2 and gassed with carbogen (O2 95%, CO2 5%), pH, 7.35–7.45 at constantly 37°C. 36 unipolar electrograms were recorded from the epicardial surface of both atria with regard to a reference electrode in the water-bath. Electrophysiological investigation with induction of arrhythmias was performed as described previously [37]. Intracardiac atrial and ventricular recording and atrial stimulation maneuvers were performed using a CardioTek EPTracer (Biotronik). Bipolar electrograms were obtained from each electrode pair during the whole procedure. Programmed atrial stimulation was performed at pacing stimulus amplitudes of 1.0 and 2.0 mA with 7 stimuli fixed rate at S1S1 cycle length of 120 ms, 110 ms and 100 ms, respectively, with one short coupled extra stimulus with a 10 ms-stepwise S1S2 reduction starting at cycle length of 80 ms down to 10 ms. Atrial refractory period (ARP) was determined, which was defined as longest S1S2 with absent atrial response in the most representative intracardiac tracing. Atrial burst stimulation was performed for 1 sec (three times consecutively) at S1 stimulation cycle lengths starting at 50 ms with 10-ms stepwise reduction down to 10 ms at pacing stimulus amplitudes of 1.0 and 2.0 mA. Between these stimulation procedures, a 10-sec recovery period was maintained. Atrial fibrillation was defined by presence of rapid and fragmented atrial electrograms in combination with irregular AV-nodal conduction and ventricular rhythm with a duration of these atrial electrograms of more than one second [38]. Number of AF episodes and AF duration (last stimulus-spike to the first sinus-rhythm P wave) were analyzed.

Thereafter, blood was drawn from the caval vein into heparinized syringes, hearts were flushed with saline via left ventricular puncture and hearts were excised. Hearts were either fixed in 3.7% paraformaldehyde solution and embedded in paraffin, embedded in optimal cutting temperature compound (OCT) and frozen to −80°C or atria and ventricles were dissected and snap frozen in liquid nitrogen.
derivative of each unipolar electrogram was evaluated and
maximal negative dV/dt activation was defined as the time-point
of maximum local activation. With regard to myocardial fiber
orientation, longitudinal and transversal conduction velocities
(CV) were evaluated by calculating latencies between two
electrodes, divided by the interelectrode distance.

**Immunofluorescence analysis**

OCT embedded samples were cut to 3 μm sections and fixed
with 3.7% formaldehyde. Tissue was permeabilized with 0.1%
Triton-X 100 and treated with primary antibodies to murine
Ly6G (Hycult Biotechnology, 1:40) and MPO (Thermo Scientific,
1:100) or for human sections to MPO (Calbiochem, 1:200) and
Alexa-Fluor-conjugated secondary antibodies (Invitrogen, 1:200).
Nuclei were stained with DAPI.Images of MPO and PMN in
atrial tissue were captured with a CCD camera mounted on a
Leica DMLB microscope with IVision software. Number of PMN
was counted in 4–5 fields of view (magnification ×40) per atrium.

**Determination of MPO levels in heart perfusates**

To release MPO from its binding to the vascular endothelium
of the coronary circulation, hearts of anaesthetized mice were
explanted and immediately cannulated via the aorta. Hearts were
rinsed retrogradely with 200 μl of PBS followed by perfusion with
2 ml of heparin solution (5 I.U./ml). The perfusate was concen-
trated by vacuum centrifugation to 40 μl and the MPO
concentration was determined by ELISA following manufacturer’s
instructions (Hycult Biotechnology).

**Determination of MPO levels in atrial homogenates**

Samples were homogenized in lysis buffer (20 mM Tris-HCl
pH 7.5, 250 mM sucrose, 20 mM EDTA, 3 mM EGTA, 0.1%
Triton X-100, supplemented with 10× EDTA-free Protease
Inhibitor Tablets and 10× PhoSTOP, Roche Diagnostics) using
the Tissue Lyzer (Qiagen). Homogenates were centrifuged at
14,000 g (4°C, 10 min) and the supernatant was recovered. MPO
was quantified using an ELISA (Hycult Biotechnology) according
to the manufacturer’s instructions. Total protein amount in samples
was assessed with BCA-protein assay (Pierce). MPO levels were
related to total protein.

**Immunoblot**

Hearts were explanted from anaesthetized mice, rinsed in ice
cold PBS and atria were dissected from ventricles. The tissue was
snap frozen in liquid nitrogen and stored at
−80°C. Samples were
homogenized in lysis buffer as described above. Homogenates
were centrifuged at 14,000 g (4°C, 10 min) and the supernatant
was recovered. Proteins were separated by SDS-PAGE and
transferred to nitrocellulose membranes. After blocking with 5%
nonfat milk in TBST (20 mM Tris-HCl pH 7.5, 137 mM NaCl,
0.1% (v/v) Tween 20), membranes were incubated with primary
antibodies to ICAM-1 (1:200), Santa Cruz Biotechnology),
VCAM-1 (1:200), Santa Cruz Biotechnology) or GAPDH
(1:2,500, Cell Signaling Technology), followed by horseradish
peroxidase-conjugated secondary antibodies (1:10,000, Vector
Laboratories) and chemiluminescence signals were detected with
a Fusion FX Advance (Vilber Lourmat) and analyzed densiome-
trically with Fusion-CAPT software (Vilber Lourmat).

**Determination of atrial fibrosis**

Longitudinal sections (4 μm) of paraffin embedded hearts were
prepared and stained with Trichrome stain following a standard
protocol. The area in atrial sections, which was stained in light
blue (excluding pericardium), was quantified using color threshold
and planimetry with Keyence BZII Analyzer (Keyence) software.

**Patients with AF**

Right atrial appendages were obtained from patients undergo-
ing elective coronary artery bypass surgery, either from patients
with persistent AF or without AF.

**Statistical analysis**

Continuous variables were tested for normal distribution by
using the Kolmogorov-Smirnoff test. Data are presented as mean
± SEM or as median (line) and interquartile range (box); whiskers
indicate 5% and 95% percentiles. Statistical analysis was performed
by one-way ANOVA followed by Bonferroni or LSD post hoc test for normally distributed data, or Kruskal-Wallis test
with Mann-Whitney-U post hoc test, as appropriate. For compar-
ison of two groups of non-normally distributed data, Mann-
Whitney U test was used. A value of P<0.05 was considered
statistically significant. All calculations were carried out by using
SPSS Statistics 20 for Mac.

**Results**

To induce leukocyte activation in wild type (WT) and CD11b/
CD18 integrin-deficient (CD11b−/−) mice, Ang II was infused
subcutaneously for 14 days by osmotic minipumps. Immunohis-
tochemical analysis of atrial sections revealed increased atrial
infiltration of PMN in WT mice (n = 13) as compared to vehicle
treated animals (n = 6; p<0.05). This Ang II-dependent increase in
PMN extravasation proved to be CD11b-dependent, since mice
devoid of the integrin did not demonstrate any significant increase
in extravascular deposition of PMN in the atria (Ang II: n = 15,
vehicle: n = 7; p = 0.09) (Fig. 1A, B). Immunoblot analyses of the
amount of endothelial CD11b/CD18 binding partners revealed that the protein amounts of ICAM-1 (WT ctrl, Ang II: n = 6, 9,
CD11b−/− ctrl, Ang II: 6, 6) and vascular cell adhesion molecule-
1 (VCAM-1) (WT ctrl, Ang II: n = 5, 10; CD11b−/− ctrl, Ang II:
n = 5, 5) were slightly enhanced following Ang II application as
compared to untreated animals, but were not different between
Ang II treated WT and Ang II treated CD11b−/− mice (ICAM-1
p = 0.12; VCAM-1 p = 0.98) (Fig. 1C, D). Immunoblot analyses of
the amount of endothelial CD11b/CD18 binding partners revealed
significantly lower MPO concentrations in atrial homogenates of
CD11b−/− mice upon Ang II treatment (n = 5) as compared to
Ang II treated WT mice (n = 11, p<0.05) (Fig. 1E). Likewise, the
amount of endothelial bound MPO within the coronary vascula-
ture was markedly lower in Ang II treated CD11b−/− (n = 4) as
compared to Ang II treated WT mice (n = 7; p<0.01), thereby also
indicating a decrease in cardiac MPO accumulation due to
CD11b/CD18 deficiency (Fig. 1F).

To investigate whether increased atrial PMN infiltration and
enhanced cardiac MPO deposition translates into aggravated
atrial remodeling, we analyzed atrial fibrosis in WT and CD11b/
CD18 integrin-deficient (CD11b−/−) mice, Ang II was infused
subcutaneously for 14 days by osmotic minipumps. Immunohis-
tochemical analysis of atrial sections revealed increased atrial
infiltration of PMN in WT mice (n = 13) as compared to vehicle
treated animals (n = 6; p<0.05). This Ang II-dependent increase in
PMN extravasation proved to be CD11b-dependent, since mice
devoid of the integrin did not demonstrate any significant increase
in extravascular deposition of PMN in the atria (Ang II: n = 15,
vehicle: n = 7; p = 0.09) (Fig. 1A, B). Immunoblot analyses of the
amount of endothelial CD11b/CD18 binding partners revealed that the protein amounts of ICAM-1 (WT ctrl, Ang II: n = 6, 9,
CD11b−/− ctrl, Ang II: 6, 6) and vascular cell adhesion molecule-
1 (VCAM-1) (WT ctrl, Ang II: n = 5, 10; CD11b−/− ctrl, Ang II:
n = 5, 5) were slightly enhanced following Ang II application as
compared to untreated animals, but were not different between
Ang II treated WT and Ang II treated CD11b−/− mice (ICAM-1
p = 0.12; VCAM-1 p = 0.98) (Fig. 1C, D). Immunoblot analyses of
the amount of endothelial CD11b/CD18 binding partners revealed
significantly lower MPO concentrations in atrial homogenates of
CD11b−/− mice upon Ang II treatment (n = 5) as compared to
Ang II treated WT mice (n = 11, p<0.05) (Fig. 1E). Likewise, the
amount of endothelial bound MPO within the coronary vascula-
ture was markedly lower in Ang II treated CD11b−/− (n = 4) as
compared to Ang II treated WT mice (n = 7; p<0.01), thereby also
indicating a decrease in cardiac MPO accumulation due to
CD11b/CD18 deficiency (Fig. 1F).

To investigate whether increased atrial PMN infiltration and
enhanced cardiac MPO deposition translates into aggravated
atrial remodeling, we analyzed atrial fibrosis in WT and CD11b−/−
mice. Evidenced by increased deposition of matrix proteins, Ang
II treatment resulted in profoundly augmented atrial fibrosis
compared to vehicle treated WT mice (n = 13, 12; p<0.001).
Remarkably, the genesis of atrial fibrosis in Ang II treated
CD11b−/− mice was blunted (WT Ang II vs. CD11b−/− Ang II
p<0.05) and not different if compared to vehicle-treated
CD11b−/− mice (n = 6; p = 0.24; Fig. 2A–C).

Next, we tested whether increased presence of PMN and
aggravated atrial fibrosis translate into a lower threshold for
initiation of atrial fibrillation. Therefore, we performed in-vivo
electrophysiological investigations as described previously [37].
Figure 1. Atrial PMN infiltration and MPO accumulation was attenuated by CD11b-deficiency. (A) Number of MPO- and Ly6G-positive leukocytes in atrial sections of WT and CD11b\(^{-/-}\) mice upon vehicle or Ang II treatment was quantified in 4–5 FOVs per atrium (FOV = field of view, \(\times 40\)). * = \(p < 0.05\), *** = \(p < 0.001\). (B) Representative images of immunofluorescence staining of PMN in mouse atrial tissue: blue = DAPI, red = Ly6G, green = MPO. Arrowheads indicate leukocytes. Scale bar = 50 \(\mu m\). (C, D) Protein expression of ICAM-1 and VCAM-1 in atrial tissue of WT and CD11b\(^{-/-}\). (E, F) MPO concentration in atrial tissue of WT and CD11b\(^{-/-}\).
Upon controlled local right atrial burst stimulation, inducibility and length of atrial fibrillation was captured. As shown in Fig. 3 WT mice exposed to Ang II (n = 18) revealed markedly increased vulnerability to AF: Number of AF episodes as well as the length of AF episodes were significantly increased as compared to vehicle treated animals (n = 10; p < 0.05). In contrast, CD11b^−/− mice were protected from the AF-provoking effect of Ang II (n = 8, 12; WT Ang II vs. CD11b^−/− Ang II p < 0.05) (Fig. 3 A–C). In line with this, P-wave duration was prolonged in Ang II treated WT mice in contrast to CD11b^−/− mice (p < 0.01) (Table 1). In support of these results from electrophysiological investigations, epicardial mapping analyses revealed, that electrical conduction velocity was decreased following chronic Ang II infusion in WT mice (n = 7, 6; Ang II vs. vehicle p < 0.001). This deceleration was blunted in CD11b^−/− mice (p = 0.6; n = 7; Ang II WT vs. CD11b^−/− p < 0.001) (Fig. 3D, E).

Finally, we determined the amount of MPO-positive leukocytes in right atrial appendage tissue of patients with persistent AF (n = 5) or without AF (n = 4), which revealed a significantly increased number of leukocytes with enhanced MPO-deposition in sections of patients with AF as compared to control subjects (p < 0.05) (Fig. 4A, B).

**Discussion**

In the current study we revisited the biological significance of CD11b/CD18 integrin-dependent cardiac recruitment of PMN for atrial fibrosis and AF.

We have reported recently that MPO, stored in primary granules of PMN and released by the cells upon activation, links atrial fibrosis and the susceptibility for atrial fibrillation [25]. However, whether leukocytes are critical for the local distribution of MPO into the tissue has not been answered so far. The current data now show that reduced PMN infiltration in CD11b^−/− mice.

---

**Figure 2. Angiotensin II-induced atrial fibrosis was reduced in CD11b^−/− mice.** (A) Percentage of fibrotic area in atrial sections of WT and CD11b^−/− mice upon vehicle or Ang II treatment. * = p < 0.05, ** = p < 0.001. (B, C) Representative images of Trichrome stained atrial sections with fibrotic tissue stained in light blue merged from 6 individual images with 10× magnification (B), scale bar = 200 μm and with 40× magnification (C), scale bar = 40 μm.

doi:10.1371/journal.pone.0089307.g002
Figure 3. CD11b-deficiency diminished AF vulnerability and preserved conduction velocity following angiotensin II treatment. (A, B) Number and total time of AF-episodes during an electrophysiological stimulation procedure in WT and CD11b−/− mice upon vehicle or Ang II application. * = p<0.05. (C) Example electrical tracings of surface and intracardiac leads from Ang II treated WT and CD11b−/− mice during electrophysiological burst stimulation with cycle length of 20 ms. (D) Electrical conduction velocity in propagation direction as assessed by epicardial mapping of Langendorff-perfused hearts of WT and CD11b−/− mice. *** = p<0.001. (E) Representative examples of conduction properties of epicardial activation mapping.

doi:10.1371/journal.pone.0089307.g003
increased inflammatory milieu in CD11b-expressing cells like macrophages and natural killer cells. Interestingly, a more recent study also supports CD11b-dependent integrin knockout has repeatedly been shown to prevent local PMN extravasation [36,39,40], implying a direct negative effect of attenuated atrial PMN infiltration on atrial remodeling. Other potential mechanisms include impaired leukocyte - extracellular matrix interactions [41] and diminished responses of other CD11b expressing cells like macrophages and natural killer cells. Interestingly, a more recent study also supports CD11b-dependent internalization of MPO by endothelial cells [35], thereby providing an additional pathobiological mechanism for a decreased inflammatory atrial milieu in CD11b -/- mice, independently of PMN infiltration itself.

The current study now expands our understanding on the basic mechanisms linking inflammation, atrial remodeling and the development of atrial fibrosis in an important way: The current data reveal that leukocytes, in particular PMN are not only bystanders of AF but at best function as circulating carriers of effector proteins, which then propagate atrial remodeling. Moreover, our results reveal that intimate contact of PMN with the atrial vasculature and PMN recruitment into atrial tissue represent relevant components of atrial fibrosis. Whereas this is accompanied with release of MPO, the enzyme is most probably not the exclusive effector, by which PMN increase the burden of fibrosis in the atria. Superoxide, generated by the cells NADPH oxidase, by uncoupled NO-synthases or released by mitochondria is closely linked to the initiation of fibrosis and AF [42,43]. However the contribution of leukocytes as critical effectors in the pathophysiology of AF has probably been underestimated so far.

Angiotensin II is appreciated as a central effector peptide allowing for atrial remodeling and ultimately the induction of AF [44]. However, these proarrhythmic effects were mainly attributed to the local, myocyte-directed effects of Ang II yielding increased superoxide generation, matrix production and cellular hypertrophy. Interestingly, acute Ang II-mediated proarrhythmic effects in a rat model of ventricular arrhythmia were shown to be dependent on the presence of an aged and more fibrotic myocardium rather than on the occurrence of Ang II induced early afterdepolarizations alone [45]. Given that Ang II-mediated leukocyte activation in the absence of CD11b/CD18-integrins exerted only a slight proarrhythmic effect suggests, that the cytokine-like, leukocyte-activating properties of this peptide contribute to its arrhythmogenicity. Certainly, this does not necessarily imply that inhibition of Ang II-signaling is beneficial in the prevention or therapy of AF, as PMN can be activated by various other stimuli. In fact, inflammatory markers like high-sensitive CRP (hsCRP) and IL-6 are elevated in patients with recurrent AF in an early non-permanent stage of AF [46], but these particular patients did not benefit from Ang II receptor inhibition [47]. However, meta-analyses show an overall beneficial effect for Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) in primary and secondary prevention of AF [48,49], especially in patients already suffering from recurrent AF.

Table 1. Electrophysiological parameters derived from surface ECGs.

|                  | WT vehicle | WT Ang II | CD11b -/- vehicle | CD11b -/- Ang II | P-value |
|------------------|------------|-----------|-------------------|-----------------|---------|
| P (ms)           | 12.6±0.3   | 14.1±0.3  | 12.3±0.3          | 12.8±0.5        | *0.003  |
| ARP (ms)         | 37±5.4     | 38.8±2.3  | 37.8±3.2          | 43.7±3.2        | n.s.    |
| QRS (ms)         | 12.6±0.5   | 13.2±0.4  | 12.4±0.3          | 12.5±0.4        | n.s.    |
| QTc (ms)         | 153.8±8.1  | 156.2±5.5 | 158.3±3.0         | 143.3±5.9       | n.s.    |
| HR (bpm)         | 334±14     | 345±11    | 330±12            | 327±14          | n.s.    |

*P, P-wave duration; ARP, atrial refractory period; QRS, QRS duration; QTc, QT interval corrected for heart rate; HR, heart rate; bpm, beats per minute; n.s., not significant.

doi:10.1371/journal.pone.0089307.t001

Figure 4. Atrial PMN-infiltration was enhanced in patients with AF. (A) Number of MPO-positive leukocytes in sections of atrial appendages of control subjects and patients with persistent AF (FOV = field of view, ×40). (B) Representative images of immunoreactivity for MPO (green) in human atrial appendage sections. Scale bar = 15 μm.
doi:10.1371/journal.pone.0089307.g004
or with concomitant diseases like hypertension or heart failure. Given the increasing effects of ACE inhibitors and ARBs in patients with exaggerated disease in humans, augmented atrial fibrosis is most likely the result of a variety of pathways, with one of the C-reactive protein being mediated by PMN.

Limitations of the current study arise from the fact that we only studied rodents and do not provide data helping to translate the current results into a clinical setting. Furthermore, we investigated AF, which was induced by electrical stimulation instead of detecting spontaneous occurrence of the arrhythmia, e.g. in an aging cohort of animals.

However, the data clearly reveal the significance of CD11b/CD18 integrins for the initiation and perpetuation of AF, furthermore underscore the role of fibrosis for this disease and call for a more in-depth evaluation of inflammatory mechanisms underlying AF in human pathophysiology.

Acknowledgments

The authors want to thank Hartwig Wieboldt and Gülşah Duman for expert technical assistance.

Author Contributions

Conceived and designed the experiments: KF MA SB AK. Performed the experiments: KF MA MM LR TR FS FD. Analyzed the data: KF MA AK MM RPA JWS GN SW. Wrote the paper: KF MA AK SB.

References

1. Kannel WB, Abbott RD, Savage DD, McNamara PM (1982) Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 306: 1018–1022.
2. Stewart S, Hart CL, Hole DJ, McMurray JJV, Pencina MJ, et al (2010) A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 119: 359–364.
3. Kirchhof P, Aurichio A, Bas J, Crijns H, Camm J, et al (2007) Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J 28: 2803–2817.
4. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 12: 1360–1420.
5. Weerasooriya R, Khairy P, Litalien J, Macle L, Hocini M, et al (2011) Catheter ablation for atrial fibrillation: are results maintained at 5 years of follow-up? J Am Coll Cardiol 57: 160–166.
6. Ouyang F, Tilz R, Chun J, Schmidt B, Wissner E, et al (2010) Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation 122: 2300–2307.
7. Goudis GA, Kallegris EM, Vardas PE (2012) Extracellular matrix alterations in the atria: insights into the mechanisms and perpetuation of atrial fibrillation. Europace 14: 623–630.
8. Friedrichs K, Klinke A, Baldus S (2011) Inflammatory pathways underlying atrial fibrillation. Trends Mol Med 17: 536–543.
9. Friedrichs K, Baldus S, Klinke A (2012) Fibrosis in Atrial Fibrillation - Role of Integrins for the Initiation and Perpetuation of AF. J Am Coll Cardiol 59: 160–166.
10. Ouyang F, Tilz R, Chun J, Schmidt B, Wissner E, et al (2010) Long-term results of catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation 122: 2300–2307.
11. Goudis GA, Kallegris EM, Vardas PE (2012) Extracellular matrix alterations in the atria: insights into the mechanisms and perpetuation of atrial fibrillation. Europace 14: 623–630.
12. Friedrichs K, Klinke A, Baldus S (2011) Inflammatory pathways underlying atrial fibrillation. Trends Mol Med 17: 536–543.
13. Kirchhof P, Aurichio A, Bas J, Crijns H, Camm J, et al (2007) Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J 28: 2803–2817.
14. Dernellis J, Panaretou M (2004) Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Am Heart J 148: 462–466.
15. Dernellis J, Panaretou M (2004) Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 25: 1100–1107.
16. Heininger KM, Therkelsen SK, Bruunsgaard H, Krabbe KS, Pedersen BK, et al (2009) Prognostic impact of hs-CRP and IL-6 in patients with persistent atrial fibrillation treated with electrical cardioversion. Scand J Clin Lab Invest 69: 425–432.
17. Goudis GA, Kallegris EM, Vardas PE (2012) Extracellular matrix alterations in the atria: insights into the mechanisms and perpetuation of atrial fibrillation. Europace 14: 623–630.
18. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, et al (2003) Inflammation as a risk factor for atrial fibrillation. Circulation 108: 3006–3010.
19. Conway DS, Buggins P, Hughes E, Lip GY (2004) Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J 148: 462–466.
20. Smith JG, Newton-Cheah C, Almgren P, Sruck J, Morgenthaler NG, et al (2010) Association between markers of vascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol 56: 1712–1719.
21. Bruins P, te Velthuijzen HA, Zaanenbakah AH, Jansen PG, van Hardervel FV, et al (1997) Activation of the complement system during and after cardio pulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 96: 3542–3548.
22. Ramlavi B, Otu H, Mieno S, Boodhwani M, Sodha NR, et al (2007) Oxidative stress and atrial fibrillation after cardiac surgery: a case-control study. Ann Thorac Surg 94: 1166–1172–3.
23. Lamm G, Auer J, Weber T, Berent R, Ng C, et al (2006) Postoperative white blood cell count predicts atrial fibrillation after cardiac surgery. J Cardiothorac Vasc Anesth 20: 51–56.
24. Rudolphi V, Andrieu RP, Rudolphi TK, Friedrichs K, Klinke A, et al (2010) Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med 16: 470–474.
25. Okumura T, Watanabe I, Nakai T, Okahara K, Kofumi T, et al (2011) Impact of biomarkers of inflammation and extracellular matrix turnover on the outcome of atrial fibrillation ablation: importance of matrix metalloproteinase-2 as a predictor of atrial fibrillation recurrence. J Cardiovasc Electrophysiol 22: 907–913.
26. Ding ZM, Babensee JE, Simon SI, Lu H, Perrard JL, et al (1999) Relative contribution of LFA-1 and Mac-1 to neutrophil adhesion and migration. J Immunol 163: 5029–5038.
27. Harris LS, McIntyre TM, Prescott SM, Zimmerman GA (2000) The leucocyte integrins. J Biol Chem 275: 23409–23412.
28. Mocsai A, Ligeti E, Lowell CA, Berton G (1999) Adhesion-dependent degranulation of neutrophils requires the Src family kinases Fgr and Hck. J Immunol 162: 1120–1125.
29. Murdoch C, Fain A (2000) Chemokine receptors and their role in inflammation and infectious diseases. Blood 95: 3032–3043.
30. Hughes BJ, Hollers JC, Beauty CR, Smith CW (1992) Recruitment of CD11b/CD18 neutrophils during the synthesis and migration of LFA-1. Blood 993.
31. Hughes BJ, Hollers JC, Beauty CR, Smith CW (1992) Recruitment of CD11b/CD18 neutrophils during the synthesis and migration of LFA-1. Blood 993.
32. Ross GD (2002) Role of the lectin domain of Mac-1/CR3 (CD11b/CD18) in regulating intracellular adhesion. Immunol Res 25: 219–227.
33. Zhou MJ, Boson EJ (1994) CR3 (Mac-1, alpha beta 2, CD11b/CD18) and Fe gamma RIIH cooperate in generation of a neutrophil respiratory burst: requirement for Fe gamma RII and tyrosine phosphorylation. J Cell Biol 125: 1407–1416.
34. Liao D, Molina H, Eiserich JP, Freeman BA, Daiber A, et al (2005) Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc Natl Acad Sci U S A 102: 431–436.
35. Jerke U, Rolle S, Pflugfert B, Latt FC, Nauseef WM, et al (2013) A novel role for the beta 2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation. Immunity 35: 563–566.
Walzog B, Schuppan D, Heimpel C, Hafezi-Moghadam A, Gaehtgens P, et al (1995) The leukocyte integrin Mac-1 (CD11b/CD18) contributes to binding of human granulocytes to collagen. Exp Cell Res 218: 28–38.

Reil JC, Hohl M, Oberhofer M, Kazakov A, Kaefer M, et al (2010) Cardiac Rac1 overexpression in mice creates a substrate for atrial arrhythmias characterized by structural remodelling. Cardiovasc Res 87: 485–493.

Sovari AA, Morita N, Karagueuzian HS (2008) Apocynin: a potent NADPH oxidase inhibitor for the management of atrial fibrillation. Redox Rep 13: 242–245.

Novo G, Guttilla D, Fazio G, Cooper D, Novo S (2008) The role of the renin-angiotensin system in atrial fibrillation and the therapeutic effects of ACE-I and ARBs. Br J Clin Pharmacol 66: 345–351.

Bapat A, Nguyen TP, Lee JH, Sovari AA, Fishbein MC, et al (2012) Enhanced sensitivity of aged fibrotic hearts to angiotensin II- and hypokalemia-induced early afterdepolarization-mediated ventricular arrhythmias. Am J Physiol Heart Circ Physiol 302: H2331–H2340.

Masson S, Aleksova A, Favero C, Staszewsky L, Bernardinangeli M, et al (2010) Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation: data from the GISSI atrial fibrillation trial. Heart 96: 1909–1914.

Disertori M, Latini R, Bardera S, Franceschi MG, Staszewsky L, et al (2009) Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360: 1606–1617.

Khalf R, Joseph P, Briel M, Yusuf S, Healey J (2013) Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials. Int J Cardiol 165: 17–24.

Huang G, Xu JB, Liu JX, He Y, Nie XL, et al (2011) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis. Eur J Clin Invest 41: 719–733.